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eLaboratorio de Estudios Cristalográficos, IACT, CSIC-Universidad de Granada, Av. de las Palmeras 4, 18100 Armilla,
Granada, Spain
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Tributyltin/iodinationAbstract Two distinct series of the 3-amino-1,5-benzoxathiepin scaffold, derived from L-cysteine,
were synthesized and evaluated for their anti-proliferative activity in the breast cancer MDA-MB-
231 and MCF-7 cells, and in the ovarian carcinoma SKOV-3 cell line. (3R)-Amino-3,4-dihydro-2H-
1,5-benzoxathiepin [(R)-10] was diversified into two forms: (a) by incorporating different amino
acids at its position 3, through an amide bond; and (b) by construction of the purine ring to give
6-chloro-9-[2-(3,4-dihydro-2H-1,5-benzoxathiepin-(3R)-yl)]-9H-purine [(R)-28]. Nevertheless, when
the introduction of iodine was tried at position 2 of the purine ring of (R)-28, 2-{[2-(6-chloro-2-
iodo-9H-purin-9-yl)prop-2-en-1-yl]thio}phenol (34) was obtained. Compound 34 shows activity
against cancer cells. Interestingly, 34 inhibits mammosphere formation at the micromolar range,, 18071
Cysteine-based 3-substituted 1,5-benzoxathiepin derivatives 427demonstrating activity against cancer stem cells. Although further studies of its targets and mech-
anism of action are needed, these findings support the therapeutic potential of this compound in
cancer.
 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It is well known that cancer continues to be a major health problem in
developing as well as undeveloped countries. Although major advances
have been made in the chemotherapeutic management of some
patients, the continued commitment to the laborious task of discover-
ing new anticancer agents remains critically important, in the course of
identifying various chemical substances which may serve as a lead for
designing novel anti-tumor agents.
Breast cancer still remains as the second most common cancer
worldwide. Although chemotherapy and radiotherapy can effectively
reduce tumor mass and provide temporary remission, relapse occurs
in many cases. This is due to an intrinsically chemotherapy-resistant
subpopulation of cells with a strong ability for self-renewal, known
as cancer stem cells (CSCs) (Li et al., 2008). This subset of cells may
also contribute to tumor initiation, progression and metastasis. Thus,
drugs that target CSCs offer great promise for cancer treatment, par-
ticularly in combination with chemotherapy (Garcı́a-Rubiño et al.,
2016).
The design, synthesis and biological evaluation of a series of 2- and
6-disubstituted (RS)-9-(2,3-dihydro-1,4-benzoxathiin-3-ylmethyl)-9H-
purine derivatives and the most active compounds as anti-
proliferative agents were 1 and 2 (Fig. 1) (Dı́az-Gavilán et al., 2008).
We have also reported the synthesis and anti-proliferative activity
against the human breast cancer cell line MCF-7 of a series of substi-
tuted (RS)-9-(2,3-dihydro-1,4-benzoxathiin-2-ylmethyl)-9H-purines
12–14. The most active compound (RS)-2,6-dichloro-9-(2,3-dihydro-1
,4-benzoxathiin-2-ylmethyl)-9H-purine (5) shows an IC50 = 2.75
± 0.02 lM (Fig. 1) (Conejo-Garcı́a et al., 2011).
The issue of chiral drug is now a major theme in the design, discov-
ery and development of new drugs. It has been shown that for many
pharmaceuticals only one enantiomer contains the desired activity,
and the synthesis of such drug molecules in their optically pure form
is becoming increasingly important. We have recently reported an effi-
cient enantiospecific synthesis of the (R)- and (S)-9-(2,3-dihydro-1,4-
benzoxathiin-2 and 3-ylmethyl)-9H-purines 3–5 under microwave
(MW) irradiation, together with the mechanism and their correspond-
ing anti-tumor activity against the human breast cancer cell lines
MCF-7 and SKBR-3. All homochiral compounds included in this
study show different apoptotic effects between both enantiomers
(Garcı́a-Rubiño et al., 2013).
Preparation has been developed for alkylated aminopurines with
the (R)- and (S)-3,4-dihydro-2H-1,5-benzoxathiepin-3-ol moieties by
the Mitsunobu reaction under microwave-assisted conditions. It
reveals a complete inversion of the stereogenic center of the secondary
alcohol giving an alkylated adenine linked to a homochiral six-
membered ring (Garcı́a-Rubiño et al., 2014). In both publications,
when (RS)-3-hydroxy-3,4-dihydro-2H-1,5-benzoxathiepin reacts with
several purines under the Mitsunobu conditions, a contraction of the
seven-membered ring takes place into the six-membered one. The reac-
tions deviate from the normal behavior because the sulfur atom com-
petes as an alternative nucleophile, through an intermediate
episulfonium ion (Garcı́a-Rubiño et al., 2014, 2013).
The secondary hydroxyl group was previously transformed into the
hydroxyethyleneoxy or hydroxypropyleneoxy fragments. This allowed
the separation of a newly generated primary hydroxyl group of the
seven-membered cycle in order to prevent the S-3 participation of
neighboring group and concomitant contraction of the ring to a six-
membered cycle. With this objective, we published the synthesis andanti-tumor activity of a series of (RS)-9-[3-(3,4-dihydro-2H-1,5-benzox
athiepin-3-yloxy)alkyl]-9H-purines 6–8. The most active compounds
are 7 and 8 with IC50 = 6.67 ± 0.06 lM, and 5.14 ± 0.06 lM, respec-
tively (Fig. 1). Our results demonstrate that the anti-proliferative activ-
ities displayed by compounds 6–8 against the MCF-7 human breast
cancer cells are due to the inhibition of protein synthesis by the eIF-
2a phosphorylation and inhibition of the PI3K pathway (Kimatrai
et al., 2011).
Benzoxazepins are well-known pharmacophores in medicinal
chemistry showing a promising activity against various diseases such
as psychosis with a central nervous system activity along with an anti-
cancer profile against breast cancer cells (Liao et al., 1999; James et al.,
1993; Mulligan et al., 2006). One of these groups of benzoxazepins has
been identified as a target for the microtubule assembly in order to
induce anticancer activity (Mulligan et al., 2006). However, amino
acid-based benzoxazepins were little explored to evaluate their phar-
macological activity. Syntheses of amino acid-based polycycles were
reported (Mishra et al., 2007a; Mishra and Panda, 2007b, 2005). Easy
availability of amino acid-based benzoxazepins promoted Samanta
et al. (2010) to evaluate them for anticancer breast activity, and they
designed amino acid-derived benzoxazepin derivatives with alkyl
amino ethyl chains and evaluated anti-tumor activity in human breast
cancer cells and a xenograft model. The most active compound was
(S)-9 (Fig. 1) (Samanta et al., 2010).
In an attempt to further explore the biological properties of ben-
zoxathiepins as active pharmacophores, we propose herein to prepare
two different structural types: (a) a new kind of L-cysteine-based 1,5-
benzoxathiepin derivatives with an amino group at position 3 of the
heterocycle with an S-configuration, and (b) a purine linked to a 1,5-
benzoxathiepin-derived structure.
2. Results and discussion
2.1. Chemistry
(3R)-Amino-3,4-dihydro-2H-1,5-benzoxathiepin [(R)-10] was
diversified into two forms: (a) the incorporation of different
amino acids through an amide bond, and (b) by the construc-
tion of the purine ring to give rise to a new prototype. The pri-
mary amine (R)-10 has been prepared according to a patent
(Vacher et al., 2005) and its synthesis is displayed in Scheme 1.
Reaction of L-cystine dimethyl ester in its form of a dihy-
drochloride salt [absolute configuration (R,R)] with the appro-
priate diazonium salt yielded the methyl (o-fluorophenyl)-L-
cysteinate [absolute configuration (R)], which was reduced
with lithium aluminum hydride to the corresponding (2R)-
amino-3-[o-fluorophenyl)sulfanyl]propan-1-ol. This amino
alcohol was finally cyclized to (R)-10. The four-step synthesis
resulted in a 51% overall yield of pure (R)-10. We have pre-
pared two derivatives of (R)-10 to confirm its structure: the
acetamide (R)-11, whose structure has been corroborated by
X-ray, and the p-nitrobenzenesulfonamide (R)-12 (Scheme 2).
2.1.1. X-ray crystallography of (R)-11
Derivative (R)-11 has been crystallized from CH2Cl2 and its
3D structure has been determined using X-ray diffraction. A
Fig. 1 Benzofused six- and seven-membered heterocycles with interesting anti-proliferative (1–8) and anticancer [(S)-9] activities.
Scheme 1 Synthesis of (R)-10 (Vacher et al., 2005).
Scheme 2 (3R)-Amino-3,4-dihydro-2H-1,5-benzoxathiepin derivatives.
428 N. Mahfoudh et al.
Cysteine-based 3-substituted 1,5-benzoxathiepin derivatives 429view of the molecule is represented in Fig. 2. Each molecule is
built up from two fused six-and seven-membered rings. The
six-membered ring is planar, whereas the seven-membered ring
displays a chair conformation with the puckering parameters:
Q2 = 0.453(3) Å and Q3 = 0.710(3) Å, /2 = 29.2(4) and
/3 = 313.2(2) (Cremer and Pople, 1975), with a total pucker-
ing amplitude of 0.842 (2) Å (Boessenkool and Boyens, 1980).
The acetamide fragment occupies an axial position in the
seven-membered ring. The absolute stereochemistry of this
homochiral molecule was confirmed by a Flack parameter of
0.003(13) (Parsons et al., 2013).
In the crystal, the acetamide moieties connect adjacent
molecules by hydrogen bonding interactions generating a
chain running along the a-axis (Fig. 3). Non-classical CAH
hydrogen bonds connect chains to build up the supramolecular
structure.
2.1.2. The 1,5-benzoxathiepin scaffold linked to distinct a-amino
acids
We have used several proteinogenic amino acids assorted on
the basis of their structure and the general chemical character-
istics of their R groups, located at position a in relation to the
carboxylic acid group: acid (Glu), aliphatic (Leu), aromatic
(Phe, Tyr), basic (Arg, Lys) and cyclic (Pro).Fig. 2 The molecular structure of (R)-3
Fig. 3 A chain obtained from hydrogen bonding interaction betwThe strategy followed is shown in Scheme 3. The reaction of
amine (R)-10 with different Boc-amino acids and subsequent
Boc-deprotection of the corresponding derivatives is summa-
rized in Table 1. Amide bond formation is a fundamentally
important reaction in organic synthesis, and is typically
mediated by the so-called coupling reagents. Valeur and Brad-
ley wrote a critical review on the most used coupling reagents
with particular attention paid to the pros and cons of these
reagents (Valeur and Bradley, 2009). We have used N-[3-
(dimethylamino)propyl]-N0-ethylcarbodiimide hydrochloride
(EDCHCl), followed by 1-hydroxybenzotriazole hydrate
(HOBt) as coupling agents for amide formation.
2.1.3. Novel purine derivatives: 1. Preservation of the 3,4-dihydro-
2H-1,5-benzoxathiepin scaffold and construction of the 6-chlorop-
urine moiety linked to the seven-membered frame. 2. Ring opening
when iodine is introduced at position 2 of the purine moiety
At this point, we have followed a different strategy (Kimatrai
et al., 2011) to preserve the seven-membered ring: We propose
herein to build up the purine ring from the amino group of the
3,4-dihydro-2H-1,5-benzoxathiepin-(3R)-yl amine (R)-10.
Starting from (R)-10 and according to Scheme 4, (R)-28 was
obtained in a sequence of two steps: a) condensation of
(R)-10 with the 5-amino-4,6-dichloropyrimidine to produce0 showing the atom labeling scheme.
een the acetamide moieties, running along the a-axis in (R)-30.
Scheme 3 General synthetic procedure for dipeptides made up by condensation of the L-cysteine-derived heterocyclic amine (R)-10 and
Boc-protected a amino acids to give 13–19, and the corresponding deprotected derivatives 20–26.
430 N. Mahfoudh et al.the substituted diaminopyrimidine (R)-27; and b) reaction
of this product with triethyl orthoformate in an acidic
medium (Scheme 4) (Dejmek et al., 2012) to produce
(R)-28.
As a part of a research program on the synthesis of some
biologically active heterocyclic compounds containing
nitrogen, we planned to synthesize some new 6-substituted
purine derivatives carrying the 9-(3,4-dihydro-2H-1,5-
benzoxathiepin-(3R)-yl)-9H-purine motif, aiming at an investi-
gation of new heterocycles with enhanced biological activity.
Scheme 5 shows several substitution products of the chlorine
atom, and a modification of the oxidation state of the sulfur
atom of (R)-28.
We have published substitution reactions on 6-chloro-7- or
9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or 9H-purines
(Núñez et al., 2006). In the present paper we find that in the
amination of (R)-28 with NH4OH, together with ammonia, a
second nucleophile arose (hydroxyl ion) and the two products
(R)-29 and (R)-30 were obtained and easily purified by flash
chromatography (CH2Cl2/MeOH: 9.9/0.1), eluting (R)-29 fas-
ter than (R)-30. In the case of (R)-31, the dimethylamine nucle-ophile results as a consequence of the decomposition of DMF
under microwave irradiation, high temperature (180 C) and
basic conditions in a sealed microwave vial. Finally, oxidation
of the sulfur atom of (R)-28 with potassium peroxymonosul-
fate (Oxone, Scheme 5) produces the sulfone (R)-32. We have
previously used this oxidation for benzo-fused sulfur-
containing seven-membered O,N-acetals (Núñez et al., 2007).
In our experience, 2,6-dihalogenopurines in general show a
better anti-proliferative activity than the 6-chloropurine
derivatives (Conejo-Garcı́a et al., 2011; Garcı́a-Rubiño et al.,
2013; Kimatrai et al., 2011; López-Cara et al., 2011; Morales
et al., 2014; Morales et al., 2015) and therefore this prompted
us to introduce an iodine atom at position 2 of the purine ring
of (R)-28. According to the work of Taddei et al. (2004), a
regioselective 2-lithiation of 6-chloropurine derivatives is
achievable at a low temperature in THF with 5 equivalents
of Harpoon0s base (lithium 2,2,6,6-tetramethylpiperidine,
LTMP). Quenching the lithiated species with 5 equivalents of
tributyltin chloride affords the 2-stannylated product exclu-
sively, and finally an iodination product under mild
conditions.
Table 1 3-(R)-Amino-3,4-dihydro-2H-1,5-benzoxathiepin has been linked to different protected a-amino acids through an amide
bond to give the protected compounds 13–19, which produce 20–26, after deprotection.








a The a amino group is protected with a Boc (tert-butyloxycarbonyl) group and the lateral chain is protected with Boc or tBu, if necessary.
b Compound 18 was obtained by treatment of {(2S)-tert-butoxycarbonylamino-N-[3,4-dihydro-2H-1,5-benzoxathiepin-(3R)-yl]-3-[4-hydrox-
ybenzene]}propiamide with 2-chloroethylpiperidine chlorhydrate.
c NaNe-Di-Boc-l-lysine hydroxysuccinimide ester.
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Scheme 5 Several substitution products of the chlorine atom, and modification of the oxidation state of the sulfur atom of (R)-28.
Scheme 4 Construction of the 6-chloropurine ring to obtain (R)-10.
432 N. Mahfoudh et al.The opening of the seven-membered ring of the non-
isolated intermediate A took place, giving rise to 33 and 34
(Scheme 6). In fact, it is well known that ethers may be cleaved
by organolithium compounds and, although the rates of these
reactions depend on both the structure of the organolithium
compound and the ether, such cleavages may occur even at
low temperatures because of the negative temperature coeffi-
cients associated with these reactions (Wakefield, 1974).
Characterization of 33 and 34 by NMR and high resolution
mass spectra (HRMS) was obtained after purification of the
crude oils by flash chromatography on silica gel [(hexane/
EtOAc: 3/1) and (hexane/EtOAc: 5/1), respectively]. In both
cases, 1H NMR (in a CDCl3 solution) showed only one purine
proton (d 8.05 ppm) assignable to H-8, as a result of a
2-substitution. The 1J, 2J, and 3J (13C-119Sn) couplings
between the tin atom and the corresponding n-butyl aliphatic
carbon atoms were observed in the 13C NMR of 33 (see Exper-
imental Part). As spectra of 33 and 34 are similar (and
therefore with the same scaffold) and in order to justify their
structures, we will develop the reasoning on the 2,6-
dihalopurine derivative 34.When 1,3-benzoxathioles were heated under reflux of ben-
zene with a lithium amide (lithium diethylamide), cleavage of
a single bond (ether and thioether) or both bonds takes place
(Melis et al., 1983). However, by performing the reaction with
LTMP at 78 C, we achieved the selective cleavage of the
ether bond of (R)-28 to produce 33. This result may seem con-
tradictory at first sight because the CAO bond dissociation
energies are usually higher than the corresponding CAS ener-
gies (Oae and Doi, 1991). However, one must consider that
hindered lithium amides such as LTMP are useful for the selec-
tive deprotonation of functionalized molecules precisely
because of the unique ability of lithium to coordinate to het-
eroatoms (Woltermann et al., 2004).
We hypothesized that the first step for the cleavage of the
ether/thioether bond of (R)-28 requires as the primary step
coordination between lithium and the heteroatom to bring
the chiral base and the substrate into close proximity, thus
enforcing the removal of the proton. Such approach was pre-
viously used by Wiedemann et al. (2003) to explain the b-
lithiation of epoxides that afford allylic alcohols, where the
lithium atom of LTMP coordinates with the epoxide oxygen
Fig. 4 Dimeric (B) and monomeric (C) aggregation/solvation
states of lithium 2,2,6,6-tetramethylpiperidine (LTMP) in tetrahy-
drofuran (THF) and the corresponding transition structures
predicted to be formed, during the b-lithiation of (R)-28.
Scheme 6 Opening of the seven-membered ring of (R)-28 when introducing iodine at position 2 of the purine ring, by using an excess of
the Harpoon0s base and tributyltin chloride, and iodine.
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base. Coordination of the oxygen to the metal would also
favor the cleavage of the C-O bond by polarizing the flanking
oxygen-carbon bonds, producing a more stable leaving group
(Houghton, 1979).
Therefore, the exclusive obtainment of 34 as the reaction
product would reflect the preferential coordination of the
lithium of LTMP with the oxygen atom (and not the sulfur)
of (R)-28, which would generate a more stable transition struc-
ture. Alternatively, the preferential abstraction of the proton
by the complex when the lithium binds to the oxygen atom
could also reflect a transition state structure where the proton
and the nitrogen are closer to the collinearity (i.e. NAHAC
optimum abstraction bond angle 180).
Wiedemann et al. (2003) also demonstrated that LTMP
exists in mixtures of THF and pentane as the C2h dimer B,
whereas low concentrations of the monomer C ( 20%)
appear in neat THF (Fig. 4). Consequently, four possible tran-
sition structures (D-G, Fig. 4) could be formed through the
coordination of lithium atoms in the aggregation/solvation
states of LTMP with the oxygen or sulfur atoms of (R)-28.
Based on the selective cleavage of the ether bond observed
for (R)-28, one may expect that the transition structures D
and F are more stable than the corresponding E and G.
Computations using density functional theory (DFT) were
then employed to detail these transition states. As the compu-
tational cost for these simulations grows exponentially with the
number of electrons of the system (Whitfield et al., 2013), we
used structures H to K (Fig. 5) as simplified models for the
transition structures D to G. According to the simulations,
the reaction is more likely to proceed via dimer-based than
monomer-based lithiation, although nearly no difference in
the enthalpy values was observed when the lithium atom of
LTMP coordinated with the oxygen or the sulfur atom. How-
ever, when we look at the NAHAC bond angles, the transition
structures I and K display considerable deviation from the
Fig. 5 Enthalpy (H) and bond angle (CHN) values calculated
for simplified models of the dimeric and monomeric transition
structures predicted to be formed during the b-lithiation of (R)-28.
434 N. Mahfoudh et al.optimum 180 collinear proton transfer angle (NAHAC
angles = 141.08 and 124.53, respectively) when compared
to the transition structures H and J (NAHAC
angles = 156.00 and 147.42, respectively), a result that is
consistent with the formation of 34.
2.2. Biological activities
MCF-7 and MDA-MB-231 human breast cancer cell lines
were selected for the in vitro assays as they have proved to
be excellent experimental models for the study of both tumori-
genesis and metastasis as well as the efficacy of different ther-
apies before its use in patients (Holliday and Speirs, 2011;
Wilhelm et al., 2004). Due to the similar genetic susceptibility
existing among breast and ovarian cancers (Miki et al., 1994),
we decided to also test the compounds in the ovarian carci-
noma SKOV-3 cell line.
Compounds evaluated for the anti-proliferative activity
have been the following: (R)-29, (R)-30, (R)-31, 37, 39–45,
(R)-46, (R)-47 and 56. To evaluate the anti-proliferative activ-
ity of the synthesized compounds, we consider active only
those that showed an IC50 value below or equal to 100 lM.
In the first chemical library only compound 37 showed an
IC50 = 100 lM in the three cancerous cell lines previously
cited.
2.2.1. Compound 34 has a selective anti-proliferative effect on
breast cancer cell lines
In relation to the purine-related compounds, 34 showed a
selective anti-proliferative activity against breast cancer cell
lines MCF-7 (IC50 = 41.8 lM) and MDA-MB-231
(IC50 = 20.4 lM), being inactive against SKOV-3. Interest-ingly, 34 did not induce significant cytotoxic effects at concen-
trations up to 100 lM in the non-tumor cell line of 142BR
fibroblasts: 85% of the cells were viable at a concentration
of 100 lM, and 91% of them at 50 lM, suggesting that the
mechanism of action of the compound is selective for cancer
cell lines.
2.2.2. Compound 34 decreases mammosphere formation in
MDA-MB-231 and MCF-7 breast cancer cells
CSCs can be identified due to the ability to grow as 3D non-
adherent structures when clonally seeded in serum-free media
(tumor-spheres), among several characteristics (Cioce et al.,
2010). We determined the effect of 34 on MDA-MB-231 and
MCF-7 breast CSCs enriched populations by growing them
into low attachment plates with sphere-forming medium for
2 weeks.
As previously described (Iglesias et al., 2013), MDA-MB-
231 cells formed weak mammospheres that could be disaggre-
gated mechanically. Nevertheless, the difference between
MDA-MB-231 cells treated with vehicle or with 34was unques-
tionable, as compound-treated cells were unable to grow as
spheres while in DMSO-treated cultures a significant number
of small-sized mammospheres were formed. In contrast to
MCF-7 spherical solid masses of cells were formed upon incu-
bation with DMSO, but this sphere formation ability was
almost completely abolished by treatment with 20 lM of 34.
Importantly, the 34-induced reduction in mammosphere
formation was not due to non-specific cytotoxicity. Previous
experiments in monolayer cultures showed that cell viability
remained as high as 60% for MDA-MB-231 cells and as
97% for MCF-7 cells in the presence of 20 lM of the
compound.3. Conclusions
The importance of sulfur in biological systems is known and also its
increasing interest as a regulatory agent. Accordingly, the rationality
that leads to the employment of sulfur-based heterocycle drugs comes
to light. On the other hand, the incorporation of alpha-amino acids
into heterocyclic structures is an effective strategy for generating
numerous peptidomimetics and combinatorial library scaffolds. We
have conducted these studies hoping to shed some light on the synthe-
sis and reactivity of seven-membered benzo-fused diheterocycles. A
diverse group of novel seven-membered heterocycles derived from nat-
urally abundant proteinogenic amino acids have been synthesized.
When (R)-28 was treated with an excess of the Harpoon’s base (lithium
2,2,6,6-tetramethylpiperidine) and tributyltin/iodination, 2-{[2-(6-
chloro-2-iodo-9H-purin-9-yl)prop-2-en-1-yl]thio}phenol (34) was
obtained as a result of breaking the O-CH2 bond of the seven-
membered ring. On the other hand, within the N-9 alkylated purines,
34 showed important activity against CSC. We are currently carrying
out its detailed mechanistic biological studies, including the identifica-
tions of possible targets for future rational drug design.4. Experimental section
4.1. General methods
Melting points were taken in open capillaries. Flash chro-
matography was performed on silica gel 60 with a particle size
of 0.040–0.063 mm (230–400 mesh ASTM). Small scale
microwave-assisted synthesis was carried out in an Initiator
Cysteine-based 3-substituted 1,5-benzoxathiepin derivatives 4352.0 single-mode microwave instrument producing controlled
irradiation at 2.450 GHz (Biotage AB, Uppsala). IR spectra
were registered on a Nicolet Avatar 360 FTIR spectropho-
tometer; vmax is given for the main absorption bands. Nuclear
magnetic resonance spectra have been carried out at the Cen-
tro de Instrumentación Cientı́fica/Universidad de Granada,
and recorded on a 300 MHz 1H and 75 MHz 13CNMR Varian
Inova-TM spectrometers at ambient temperature. On the other
hand, 1H and 13C NMR spectra recorded on a Bruker AV-400
instrument (400 MHz 1H and 100 MHz 13C NMR spectrome-
ter) at room temperature have been carried out at the Univer-
sity of Zaragoza. Chemical shifts (d) are quoted in parts per
million (ppm) and are referenced to the residual solvent peak.
Signals are designated as follows: s, singlet; bs, broad singlet,
d, doublet; dd, doublet of doublets; ddd, doublet of doublet
of doublets; dt, double triplet; t, triplet; m, multiplet. High-
resolution Nano-Assisted Laser Desorption/Ionization
(NALDI-TOF), Electrospray Ionization (ESITOF) mass spec-
tra were carried out on a Bruker Autoflex, on a Waters LCT
Premier Mass Spectrometer, and on Bruker Microtof-Q spec-
trometer. All the compounds gave accurate mass spectra, hav-
ing the correct isotope abundance and no extraneous peaks.
Small-scale microwave-assisted syntheses were carried out in
a single-mode microwave instrument producing controlled
irradiation at 2.450 GHz and sealed reaction vessels were used.
Reaction time refers to hold time from 130 C to 160 C, not to
total irradiation time. The temperature was measured with an
IR sensor outside the reaction vessel. Optical rotations were
measured in a cell with a 1 dm path length at the temperature
indicated in each case using a JASCO P-1020 polarimeter. All
evaporations were carried out in vacuum with a Büchi rotary
evaporator and the pressure controlled by a Vacuubrand
CVCII apparatus. Anhydrous DMF was used as received.4.1.1. Crystal structure determination of (R)-11
Measured crystal was prepared under inert conditions
immersed in perfluoropolyether as protecting oil for manipula-
tion. A suitable crystal was mounted on MiTeGen Micro-
mounts, and this sample was used for data collection. Data
were collected on a Bruker D8 Venture diffractometer (Cu
Ka, 150 K). Data collection and processing were performed
using the programs APEX3 (Bruker, 2016) and SAINT
(Bruker, 2013), and a multi-scan absorption correction was
applied using SADABS (Sheldrick, 2014). The structures were
solved by direct methods (Sheldrick, 2008), which revealed the
position of all non-hydrogen atoms. These atoms were refined
on F2 by a full-matrix least-square procedure using anisotropic
displacement parameters (Sheldrick, 2015). All hydrogen
atoms were located in the difference Fourier map and included
as fixed contributions riding on attached atoms with isotropic
thermal displacement parameters 1.2 (ACH, ACH2, ANAH)
or 1.5 (ACH3) times than those of the respective atoms. Crys-
tallographic data of (R)-30 for structural analysis have been
deposited in the Cambridge Crystallographic Data Centre,
CCDC 1477918.
4.1.2. Incorporation of a-amino acids into the amino group of
(R)-10
4.1.2.1. Procedure A: General procedure for amide bond
formation from amine (R)-10 and Boc-Xaa-OH. To a solution
of Boc-L-Xaa-OH (1.50 mmol) in CH2Cl2 (30 mL), cooled to0 C in an ice bath, was added N-[3-(dimethylamino)propyl]-
N0-ethylcarbodiimide hydrochloride (EDCHCl) (316 mg,
1.65 mmol) followed by 1-hydroxybenzotriazole hydrate
(HOBt) (253 mg, 1.65 mmol) and the reaction was stirred for
15 min. Then, a solution of (R)-10 (Vacher et al., 2005)
(1.24 mmol) in CH2Cl2 (10 mL) and N-methylmorpholine
(NMM) (0.18 mL, 1.65 mmol) was added and the mixture
was stirred at rt for 24 h. The reaction mixture was washed
with a 5% aqueous solution of NaHCO3 (3  30 mL), fol-
lowed by a 5% aqueous solution of KHSO4 (3  30 mL).
The organic phase was dried (MgSO4), filtered and evaporated
to dryness. The crude products were purified by column chro-
matography to provide the corresponding compounds 13–19.
4.1.2.1.1. {1-tert-Butoxycarbonyl-(2S)-[3,4-dihydro-2H-
1,5-benzoxathiepin-(3R)-carbamoyl]}pyrrolidine (13). A col-
umn chromatography (hexane/EtOAc: 3/7) afforded 13 as a
white solid (435 mg, 1.15 mmol, 93% yield). Mp: 135–
136 C. [a]D27: 15.9 (c = 0.60, acetone). IR (KBr) m: 3274,
1684, 1668 cm1. 1H NMR (MeOH-d4, 400 MHz): d 1.45 (s,
9H), 1.82–2.03 (m, 3H), 2.14–2.34 (m, 1H), 2.96 (dd, 1H,
J= 14.3 Hz, J = 6.7 Hz), 3.10 (dd, 1H, J = 14.3 Hz,
J= 3.5 Hz), 3.40–3.46 (m, 1H), 3.49–3.55 (m, 1H), 4.10–4.22
(m, 2H), 4.26 (dd, 1H, J= 8.6 Hz, J = 3.7 Hz), 4.42–4.48
(m, 1H), 6.97–7.02 (m, 2H), 7.16–7.21 (m, 1H), 7.37 (d, 1H,
J= 7.8 Hz). 13C NMR (MeOH-d4, 100 MHz): d 24.61,
25.38, 28.71, 31.35, 32.60, 36.54, 47.98, 48.25, 51.38, 61.47,
61.74, 75.07, 75.18, 81.42, 81.60, 123.11, 124.95, 129.09,
129.38, 129.80, 133.03, 156.03, 156.42, 161.73, 161.86, 174.57,
175.03. HRMS (ESI) C19H26N2NaO4S [M+Na]
+: calcd.
401.1505, found 401.1523. Anal. Calcd. for C19H26N2O4S: C,
60.29; H, 6.92; N, 7.40; Found: C, 60.32; H, 7.05; N, 7.32.
4.1.2.1.2. tert-Butyl {(1S)-[3,4-dihydro-2H-1,5-ben-
zoxathiepin-(3R)-carbamoyl]-2-phenylethyl}carbamate (14).
A column chromatography (hexane/EtOAc: 7/3) provided 14
as a white solid (522 mg, 1.22 mmol, 98% yield). Mp: 125–
127 C. [a]D28: +30.4 (c = 0.55, acetone). IR (KBr) m: 3337,
3314, 1690, 1648 cm1. 1H NMR (CDCl3, 400 MHz): d 1.41
(s, 9H), 2.85 (dd, 1H, J= 14.4, J = 5.3 Hz), 3.01 (dd, 1H,
J= 14.4, J= 2.9 Hz), 3.05–3.16 (m, 2H), 3.87 (dd, 1H,
J= 12.6, J = 2.2 Hz), 4.12 (dd, 1H, J = 12.4, J= 3.2 Hz),
4.36–4.46 (m, 1H), 4.47–4.54 (m, 1H), 5.05 (bs, 1H), 6.82 (d,
1H, J= 8.9 Hz), 6.96–7.01 (m, 2H), 7.15–7.19 (m, 1H),
7.22–7.27 (m, 3H), 7.29–7.33 (m, 2H), 7.38 (dd, 1H,
J= 7.6 Hz, J= 1.7 Hz). 13C NMR (CDCl3, 100 MHz): d
28.39, 36.33, 38.71, 48.91, 56.04, 74.35, 80.39, 122.35, 124.14,
127.17, 128.24, 128.86, 129.01, 129.42, 132.43, 136.64, 155.40,
160.88, 170.74. HRMS (ESI) C23H28N2NaO4S [M+Na]
+:
calcd. 451.1662, found 451.1673. Anal. Calcd. for C23H28N2-




A column chromatography (hexane/EtOAc: 7/3) provided 15
as a white solid (470 mg, 1.19 mmol, 96% yield). Mp: 111–
112 C. [a]D29: +24.6 (c = 0.70, acetone). IR (KBr) m: 3327,
3267, 3062, 1686, 1643 cm1. 1H NMR (CDCl3, 400 MHz): d
0.95 (d, 3H, J= 2.5 Hz), 0.97 (d, 3H, J = 2.6 Hz), 1.44 (s,
9H), 1.50–1.59 (m, 1H), 1.63–1.75 (m, 2H), 2.92 (ddd, 1H,
J= 14.4 Hz, J = 5.2 Hz, J = 1.4 Hz), 3.05 (dd, 1H,
J= 14.4 Hz, J = 2.9 Hz), 3.94 (dd, 1H, J = 12.5 Hz,
J= 2.1 Hz), 4.09–4.24 (m, 1H), 4.32 (ddd, 1H, J = 12.5 Hz,
J= 3.6 Hz, J = 1.3 Hz), 4.53–4.58 (m, 1H), 4.85–4.97
436 N. Mahfoudh et al.(m, 1H), 6.97–7.05 (m, 2H), 7.13 (d, 1H, J= 8.9 Hz), 7.17–
7.21 (m, 1H), 7.42 (dd, 1H, J= 7.7 Hz, J= 1.7 Hz). 13C
NMR (CDCl3, 100 MHz): d 22.10, 23.14, 24.94, 28.42, 36.40,
41.46, 48.84, 53.41, 74.65, 80.26, 122.44, 124.21, 128.45,
129.10, 132.54, 155.72, 161.09, 172.27. HRMS (ESI) C20H30-
N2NaO4S [M+Na]
+: calcd. 417.1818, found 417.1837. Anal.
Calcd. for C20H30N2O4S: C, 60.89; H, 7.66; N, 7.10; Found:




(16). A column chromatography (hexane/EtOAc: 7/3) yielded
16 as a white solid (759 mg, 1.19 mmol, 96% yield). Mp: 75–
77 C. [a]D28: +21.5 (c = 0.67, acetone). IR (KBr) m: 3409,
3197, 3056, 1699, 1686, 1677, 1616 cm1. 1H NMR (CDCl3,
400 MHz): d 1.44 (s, 9H), 1.46 (s, 9H), 1.51 (s, 9H), 1.64–
1.73 (m, 2H), 1.78–1.98 (m, 2H), 2.95 (dd, 1H, J = 14.4 Hz,
J= 5.6 Hz), 3.04 (dd, 1H, J = 14.3 Hz, J = 3.4 Hz), 3.84 (t,
2H, J = 7.3 Hz), 4.08–4.14 (m, 1H), 4.18–4.29 (m, 2H),
4.53–4.60 (m, 1H), 5.78 (d, 1H, J= 8.2 Hz), 6.94–7.00 (m,
2H), 7.15 (ddd, 1H, J= 8.1 Hz, J = 7.2 Hz, J= 1.7 Hz),
7.29 (d, 1H, J= 8.9 Hz), 7.36 (dd, 1H, J = 7.7 Hz,
J= 1.7 Hz), 9.22(bs, 1H), 9.35 (bs, 1H). 13C NMR (CDCl3,
100 MHz): d 25.03, 28.17, 28.33, 28.52, 35.96, 44.19, 49.35,
54.50, 74.44, 79.22, 80.12, 84.09, 122.28, 123.98, 127.87,
128.79, 132.23, 155.02, 155.84, 160.55, 160.80, 163.59, 171.85.
HRMS (ESI) C30H48N5O8S [M+H]
+: calcd. 638.3218, found
638.3227. Anal. Calcd. for C30H47N5O8S: C, 56.50; H, 7.43; N,
10.98; Found: C, 56.34; H, 7.52; N, 11.09.
4.1.2.1.5. tert-Butyl {4-tert-butoxycarbonylamino-(4S)-
[3,4-dihydro-2H-1,5-benzoxathiepin-(3R)-ylcarbamoyl]butyrate
(17). A column chromatography (hexane/EtOAc: 6/4) pro-
vided 17 as a white solid (568 mg, 1.22 mmol, 98% yield).
Mp: 57–58 C. [a]D28: +27.7 (c= 0.50, acetone). IR (KBr) m:
3375, 3277, 1717, 1702, 1672 cm1. 1H NMR (CDCl3,
400 MHz): d 1.43 (s, 9H), 1.44 (s, 9H), 1.90–2.00 (m, 1H),
2.08–2.16 (m, 1H), 2.30–2.46 (m, 2H), 2.92 (ddd, 1H,
J= 14.4 Hz, J = 5.3 Hz, J = 1.3 Hz), 3.05 (dd, 1H,
J= 14.4 Hz, J = 2.9 Hz), 3.94 (dd, 1H, J = 12.6 Hz,
J= 2.1 Hz), 4.14–4.25 (m, 1H), 4.32 (ddd, 1H, J = 12.5 Hz,
J= 3.7 Hz, J = 1.3 Hz), 4.52–4.58 (m, 1H), 5.31 (d, 1H,
J= 7.8 Hz), 6.97–7.04 (m, 2H), 7.18 (ddd, 1H, J = 8.1 Hz,
J= 7.3 Hz, J = 1.7 Hz), 7.23 (d, 1H, J= 8.9 Hz), 7.41 (dd,
1H, J= 7.6 Hz, J = 1.7 Hz). 13C NMR (CDCl3, 100 MHz):
d 27.69, 28.17, 28.38, 31.91, 36.28, 48.97, 54.32, 74.46, 80.16,
80.97, 122.37, 124.12, 128.28, 129.00, 132.44, 155.72, 160.96,
171.33, 172.66. HRMS (ESI) C23H34N2NaO6S [M+Na]
+:
calcd. 489.2030, found 489.2046. Anal. Calcd. for C23H34N2-




amide. Procedure A for amide bond formation from amine
(R)-10 and Boc-Tyr-OH, followed by column chromatography
purification (hexane/EtOAc: 4/6) provided {(2S)-tert-
butoxycarbonylamino-N-[3,4-dihydro-2H-1,5-benzoxathiepin-
(3R)-yl]-3-[4-hydroxybenzene]}propiamide as a white solid
(516 mg, 1.16 mmol, 94% yield). Mp: 94–96 C. [a]D21: +23.3
(c = 0.50, acetone). IR (KBr) m: 3311, 3063, 3010, 1699,
1658 cm1. 1H NMR (CDCl3, 400 MHz): d 1.41 (s, 9H), 2.83
(dd, 1H, J = 14.2 Hz, J = 5.3 Hz), 2.93–3.03 (m, 3H), 3.87
(dd, 1H, J= 12.6 Hz, J = 2.2 Hz), 4.04–4.17 (m, 1H), 4.30–4.43 (m, 1H), 4.43–4.53 (m, 1H), 5.22 (bs, 1H), 6.71–6.76 (m,
2H), 6.93–7.04 (m, 5H), 7.15 (ddd, 1H, J = 8.2 Hz,
J= 8.2 Hz, J= 1.7 Hz), 7.36 (dd, 1H, J = 7.6 Hz,
J= 1.6 Hz). 13C NMR (CDCl3, 100 MHz): d 28.37, 36.12,
37.82, 49.07, 56.20, 74.27, 80.65, 115.82, 122.34, 124.14,
127.60, 128.11, 129.01, 130.44, 132.41, 155.58, 160.77, 171.32.
HRMS (ESI) C23H28N2NaO5S [M+Na]
+: calcd. 467.1611,
found. 467.1613. Anal. Calcd. for C23H28N2O5S: C, 62.14;
H, 6.35; N, 6.30; Found: C, 62.32; H, 6.21; N, 6.12.
4.1.2.1.7. tert-Butoxycarbonylamino-{(1S)-[3,4-dihydro-
2H-1,5-benzoxathiepin-(3R)-ylcarbamoyl]-2-[4-(2-piperidin-1-
ylethoxy)phenyl]ethyl}carbamate (18). To a solution of {(2S)-
tert-butoxycarbonylamino-N-[3,4-dihydro-2H-1,5-benzoxathie-
pin-(3R)-yl]-3-[4-hydroxybenzene]}propiamide (444 mg,
1.0 mmol) in acetone (25 mL) was added K2CO3 (414 mg,
3.0 mmol) and NaI (19 mg, 0.13 mmol) followed by
2-chloroethylpiperidine chlorhydrate (276 mg, 1.5 mmol). The
reaction was refluxed for 24 h. Then, the mixture was filtered
and the filtrate was evaporated at reduced pressure. The crude
product was purified by column chromatography (CH2Cl2/
MeOH 9/1) to provide 18 as a white solid (500 mg, 0.9 mmol,
90% yield). Mp: 108–110 C. [a]D19: +19.1 (c= 0.50, acetone).
IR (KBr) m: 3416, 3312, 1706, 1663 cm1. 1H NMR (CDCl3,
400 MHz): d 1.41 (s, 9H), 1.45–1.52 (m, 2H), 1.63–1.71 (m,
4H), 2.55–2.67 (m, 4H), 2.82–2.83 (m, 1H), 2.85 (t, 2H,
J= 5.7 Hz), 2.97–3.12 (m, 3H), 3.86 (dd, 1H, J= 12.5 Hz,
J= 2.1 Hz), 4.13 (t, 2H, J= 5.8 Hz), 4.09–4.18 (m, 1H),
4.31–4.41 (m, 1H), 4.45–4.54 (m, 1H), 5.05 (bs, 1H), 6.76–
6.87 (m, 3H), 6.96–7.01 (m, 2H), 7.12–7.19 (m, 3H), 7.38 (dd,
1H, J= 7.7 Hz, J= 1.7 Hz). 13C NMR (CDCl3, 100 MHz):
d 23.27, 24.72, 28.30, 36.19, 37.70, 48.84, 54.63, 55.96, 57.30,
64.67, 74.28, 80.21, 114.84, 122.28, 124.05, 128.15, 128.95,
129.08, 130.42, 132.34, 155.31, 157.28, 160.78, 170.72. HRMS
(ESI) C30H42N3O5S [M+H]
+: calcd. 556.2840, found
556.2847. Anal. Calcd. for C30H41N3O5S: C, 64.84; H, 7.44;
N, 7.56; Found: C, 65.10; H, 7.25; N, 7.62.4.1.2.2. Procedure B: Procedure for amide bond formation from
amine (R)-10 and Boc-Lys(Boc)-OSu: Synthesis of 2(S),
6-di(tert-butoxycarbonylamino)-N-[3,4-dihydro-2H-1,5-ben-
zoxathiepin-(3R)-yl]hexanoamide (19). To a solution of Boc-
L-Lys(Boc)-OSu (665 mg, 1.50 mmol) in CH2Cl2 (40 mL),
cooled to 0 C in an ice bath, was added a solution of (R)-10
(1.24 mmol) in CH2Cl2 (10 mL). After stirring at rt for 24 h,
the reaction mixture was washed with a 5% aqueous solution
of NaHCO3 (3  30 mL) followed by a 5% aqueous solution
of KHSO4 (3  30 mL). The organic phase was dried
(MgSO4), filtered and evaporated to dryness. The residue
was purified by column chromatography (eluent: hexane/
EtOAc: 1/1) to provide 19 as a white solid (621 mg, 1.21 mmol,
98% yield). Mp: 61–63 C. [a]D29: +19.6 (c = 0.90, acetone). IR
(KBr) m: 3333, 1703, 1694 cm1. 1H NMR (CDCl3, 400 MHz):
d 1.32–1.53 (m, 4H), 1.37 (s, 18H), 1.57–1.69 (m, 1H), 1.76–
1.84 (m, 1H), 2.85 (ddd, 1H, J = 14.4 Hz, J = 5.3 Hz,
J= 1.4 Hz), 2.98 (dd, 1H, J = 14.4 Hz, J = 2.8 Hz), 3.02–
3.12 (m, 2H), 3.86 (dd, 1H, J = 12.6 Hz, J= 2.0 Hz), 4.02–
4.13 (m, 1H), 4.26 (ddd, 1H, J = 12.5 Hz, J = 3.6 Hz,
J= 1.3 Hz), 4.46–4.52 (m, 1H), 4.60 (bs, 1H), 5.16 (bs, 1H),
6.91–6.99 (m, 1H), 7.06 (d, 1H, J = 8.9 Hz), 7.10–7.15 (m,
1H), 7.36 (dd, 1H, J= 7.7 Hz, J = 1.7 Hz). 13C NMR
(CDCl3, 100 MHz): d 22.71, 28.42, 28.56, 29.78, 32.18, 36.34,
Cysteine-based 3-substituted 1,5-benzoxathiepin derivatives 43739.98, 48.85, 54.70, 74.58, 79.22, 80.17, 122.42, 124.22, 128.35,
129.11, 132.53, 155.80, 156.27, 161.04, 171.74. HRMS (ESI)
C25H39N3NaO6S [M+Na]
+: calcd. 532.2452, found
532.2476. Anal. Calcd. for C25H39N3O6S: C, 58.92; H, 7.71;
N, 8.24; Found: C, 58.55; H, 7.59; N, 8.49.
4.1.2.3. Procedure C for Boc deprotection. Compounds 13–
16 and 19 (0.65 mmol) were treated with a 3 M HCl solu-
tion in cyclopentyl methyl ether (5 mL) and the reaction
mixture was stirred at rt for 3 to 5 h. After completion,
the solvent was evaporated to dryness and the resulting
product was purified as indicated in each case, to yield
20–22, 25 and 26.
4.1.2.3.1. (2S)-[3,4-Dihydro-2H-1,5-benzoxathiepin-(3R)-
yl]pyrrolidine-2-carboxamide hydrochloride (20). The resulting
residue was taken up in water and lyophilized. After
lyophilization, the solid was triturated with diethyl ether and
filtered at reduced pressure to yield 20 as a white solid
(188 mg, 0.60 mmol, 92% yield). Mp: 170–172 C. [a]D27:
+1.9 (c= 0.60, methanol). IR (KBr) m: 3500–2500,
1665 cm1. 1H NMR (MeOH-d4, 400 MHz): d 2.02–2.11 (m,
3H), 2.46–2.54 (m, 1H), 3.02 (dd, 1H, J = 14.3 Hz,
J = 6.8 Hz), 3.14 (dd, 1H, J = 14.3 Hz, J = 3.6 Hz), 3.34–
3.39 (m, 1H), 3.41–3.46 (m, 1H), 4.17 (dd, 1H, J = 12.6 Hz,
J = 5.0 Hz), 4.25 (dd, 1H, J = 12.5 Hz, J = 3.0 Hz), 4.35–
4.38 (m, 1H), 4.46–4.49 (m, 1H), 6.98–7.03 (m, 2H), 7.17–
7.21 (m, 1H), 7.37 (dd, 1H, J = 7.7 Hz, J = 1.7 Hz). 13C
NMR (MeOH-d4, 100 MHz): d 25.07, 31.34, 36.13, 47.49,
52.25, 61.14, 74.81, 123.05, 124.96, 129.01, 129.76, 132.94,




zoxathiepin-(3R)-yl]-3-phenylpropionamide (21). The result-
ing residue was dissolved (H2O) and washed (CH2Cl2).
Lyophilization of the aqueous phase yielded 21 as a white solid
(179 mg, 0.49 mmol, 75% yield). Mp: 109–111 C. [a]D26: +78.4
(c= 0.60, methanol). IR (KBr) m: 3500–2500, 1672 cm1. 1H
NMR (MeOH-d4, 400 MHz): d 2.94 (dd, 1H, J = 14.3,
J = 6.9 Hz), 3.10 (dd, 1H, J = 14.3, J = 3.7 Hz), 3.11–3.21
(m, 2H), 3.84 (dd, 1H, J = 12.5, J = 5.3 Hz), 4.07 (dd, 1H,
J = 12.5, J= 3.1 Hz), 4.17 (t, 1H, J = 7.5 Hz), 4.34–4.39
(m, 1H), 6.96–7.00 (m, 2H), 7.15–7.19 (m, 1H), 7.30–7.40 (m,
6H). 13C NMR (MeOH-d4, 100 MHz): d 36.14, 38.81, 51.94,
55.67, 74.57, 123.01, 124.91, 128.84, 128.92, 129.71, 130.08,
130.59, 132.89, 135.66, 161.50, 169.10. HRMS (ESI) C18H21-
N2O2S [M+H]
+: calcd. 329.1318, found 329.1311.
4.1.2.3.3. (2S)-Amino-[3,4-dihydro-2H-1,5-benzoxathiepin-
(3R)-yl]-4-methylpentanoamide hydrochloride (22). The
resulting residue was taken up (H2O). After lyophilization,
the solid was dissolved (H2O) and washed (Et2O). Evaporation
of the aqueous phase yielded 22 as a white solid (199 mg,
0.60 mmol, 92% yield). Mp: 114–116 C. [a]D28: +40.5
(c= 0.70, methanol). IR (KBr) m: 3500–2700, 1667 cm1. 1H
NMR (D2O, 400 MHz): d 0.97 (d, 3H, J = 6.4 Hz), 0.99 (d,
3H, J = 6.4 Hz), 1.66–1.85 (m, 3H), 3.00 (dd, 1H,
J = 14.4 Hz, J = 6.3 Hz), 3.14 (dd, 1H, J = 14.5 Hz,
J = 3.1 Hz), 4.09–4.16 (m, 2H), 4.22 (dd, 1H, J = 12.8 Hz,
J = 4.8 Hz), 4.47–4.51 (m, 1H), 7.10–7.14 (m, 2H), 7.29–7.33
(m, 1H), 7.50 (dd, 1H, J = 7.6 Hz, J = 1.7 Hz). 13C NMR
(MeOH-d4, 100 MHz): d 21.16, 23.11, 25.54, 36.10, 41.86,





The resulting residue was taken up (H2O). After lyophilization,
the solid was dissolved in water and washed with diethyl ether.
Evaporation of the aqueous phase yielded 23 as a white solid
(259 mg, 0.63 mmol, 97% yield). Mp: 109–111 C. [a]D28:
+30.2 (c= 0.60, methanol). IR (KBr) m: 3500–2500,
1664 cm1. 1H NMR (D2O, 400 MHz): 1.71–1.78 (m, 2H),
1.99–2.05 (m, 2H), 3.02 (dd, 1H, J= 14.5 Hz, J= 5.9 Hz),
3.15 (dd, 1H, J = 14.5 Hz, J= 3.1 Hz), 3.28 (t, 2H,
J= 6.8 Hz), 4.13 (dd, 1H, J= 12.8 Hz, J = 2.5 Hz), 4.19 (t,
1H, J= 6.6 Hz), 4.28 (dd, 1H, J= 12.7 Hz, J= 4.8 Hz),
4.47–4.57 (m, 1H), 7.11–7.16 (m, 2H), 7.33 (ddd, 1H,
J= 8.1 Hz, J = 7.3 Hz, J = 1.7 Hz), 7.51 (dd, 1H,
J= 7.7 Hz, J= 1.7 Hz). 13C NMR (MeOH-d4, 100 MHz): d
25.51, 29.84, 36.09, 41.78, 52.19, 53.97, 74.77, 123.04, 124.95,
129.00, 129.75, 132.94, 158.54, 161.55, 169.50. HRMS
(ESI) C15H24N5O2S [M+H]




To the resulting residue, a saturated solution of NaHCO3
was added and extracted (EtOAc: 3  15 mL). The combined
organic extracts were dried (MgSO4), filtered and evaporated
to dryness. The crude compound was purified by column chro-
matography (CH2Cl2/MeOH: 8:2) to afford 25 as a white solid
(287 mg, 0.63 mmol, 97% yield). Mp: 96–98 C. [a]D18: +30.9
(c= 0.50, methanol). IR (KBr) m: 3406, 3351, 1645 cm1. 1H
NMR (CDCl3, 400 MHz): d 1.42–1.48 (m, 2H), 1.63 (tt, 4H,
J= 5.6 Hz), 1.81 (bs, 2H), 2.49–2.62 (m, 4H), 2.74 (dd, 1H,
J= 13.8 Hz, J = 8.9 Hz), 2.81 (t, 2H, J = 6.0 Hz), 2.86
(ddd, 1H, J= 14.4 Hz, J = 5.4 Hz, J = 1.3 Hz), 3.04 (dd,
1H, J = 14.3 Hz, J = 2.9 Hz), 3.16 (dd, 1H, J = 13.8 Hz,
J= 4.1 Hz), 3.64 (dd, 1H, J= 8.9 Hz, J = 4.1 Hz), 3.96
(dd, 1H, J = 12.5 Hz, J= 2.2 Hz), 4.12 (t, 2H, J= 6.0 Hz),
4.30 (ddd, 1H, J = 12.5 Hz, J= 3.8 Hz, J = 1.2 Hz), 4.52–
4.57 (m, 1H), 6.82–6.87 (m, 2H), 6.96–7.03 (m, 2H), 7.11–
7.19 (m, 3H), 7.40 (dd, 1H, J = 7.7 Hz, J = 1.7 Hz), 8.22 (d,
1H, J = 9.1 Hz). 13C NMR (CDCl3, 100 MHz): d 24.14,
25.82, 36.57, 40.26, 48.47, 55.07, 56.67, 57.93, 65.85, 74.74,
114.92, 122.38, 124.14, 128.45, 128.99, 129.81, 130.42, 132.47,
157.82, 160.98, 173.95. HRMS (ESI) C25H34N3O3S [M
+H]+: calcd. 456.2315, found 456.2309.
4.1.2.3.6. 2(S),6-Diamino-[3,4-dihydro-2H-1,5-benzoxathi-
epin-(3R)-yl]hexanoamide dihydrochloride (26). The resulting
residue was taken up (H2O). After lyophilization, the solid
was dissolved (H2O) and washed (Et2O). Evaporation of the
aqueous phase yielded 26 as a white solid (245 mg, 0.59 mmol,
90% yield). Mp: 71–73 C. [a]D27: +32.8 (c= 0.50, methanol).
IR (KBr) m: 3500–2500, 1677 cm1. 1H NMR (MeOH-d4,
400 MHz): d 1.05–1.58 (m, 2H), 1.71–1.78 (m, 2H), 1.86–2.01
(m, 2H), 2.92–3.01 (m, 2H), 3.02 (dd, 1H, J= 14.4 Hz,
J= 6.7 Hz), 3.16 (dd, 1H, J= 14.4 Hz, J= 3.6 Hz), 4.01 (t,
1H, J= 6.6 Hz), 4.22–4.23 (m, 2H), 4.45–4.50 (m, 1H), 6.99–
7.03 (m, 2H), 7.18–7.22 (m, 1H), 7.39 (dd, 1H, J= 7.6 Hz,
J= 1.7 Hz). 13C NMR (MeOH-d4, 100 MHz): d 22.96, 28.08,
32.18, 36.08, 40.29, 52.17, 54.12, 74.76, 123.02, 124.96,
129.03, 129.76, 132.96, 161.59, 169.66. HRMS (ESI) C15H24N3-
O2S [M+H]
+: calcd. 310.1584, found 310.1585.
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amino-4-[3,4-dihydro-2H-1,5-benzoxathiepin-(3R)-ylcar-
bamoyl]butyric acid trifluoroacetate (24). Compound 17
(0.65 mmol) was treated with trifluoroacetic acid (TFA) in
CH2Cl2 (3/4.5 mL) and the reaction mixture was stirred at rt
for 4 h. After evaporation of the solvent, the residue was taken
up (H2O) and washed (Et2O, 3  15 mL). Lyophilization of
the aqueous phase yielded 24 as a white solid (272 mg,
0.64 mmol, 98% yield). Mp: 73–75 C. [a]D28: +42.4
(c = 0.50, methanol). IR (KBr) m: 3500–2500, 1690,
1665 cm1. 1H NMR (MeOH-d4, 400 MHz): d 2.11–2.21 (m,
2H), 2.52 (t, 2H, J = 7.4 Hz), 3.00 (dd, 1H, J = 14.4 Hz,
J= 6.7 Hz), 3.14 (dd, 1H, J = 14.3 Hz, J = 3.6 Hz), 4.03 (t,
1H, J = 6.4 Hz), 4.18–4.26 (m, 2H), 4.44–4.49 (m, 1H),
6.97–7.03 (m, 2H), 7.16–7.21 (m, 1H), 7.37 (dd, 1H,
J= 7.7 Hz, J= 1.7 Hz). 13C NMR (MeOH-d4, 100 MHz): d
27.98, 30.72, 36.20, 52.03, 53.86, 74.78, 123.09, 124.96,
129.05, 129.77, 132.96, 161.71, 169.51, 176.20. HRMS (ESI)
C14H18N2NaO4S [M+Na]
+: calcd. 333.0879, found 333.0876.
4.1.3. Synthesis of an amide and a p-nitrobenzenesulfonamide of
(R)-10
4.1.3.1. N-(3,4-Dihydro-2H-1,5-benzoxathiepin-(3R)-yl)ac-
etamide [(R)-11]. Acetic anhydride (5 mL) was added to a
solution of (R)-10 (260 mg, 1.44 mmol) in formic acid
(16 mL) at 0 C. After 15 min the reaction mixture was
warmed to rt and was stirred for further 16 h. Then, the sol-
vent was removed and the reaction mixture was extracted with
EtOAc. The organic layer was washed with H2O and brine,
dried (Na2SO4), filtered and concentrated in vacuum. The
crude was purified by column chromatography (CH2Cl2/
MeOH: 9.5/0.5) to afford (R)-11 (222 mg, 85%), as a micro-
crystalline white solid. Mp 220–222 C; [a]D26 + 18.3 (c = 1,
in MeOH); 1H NMR (300 MHz, DMSO-d6): d 8.14 (1H, d,
J= 7.5 Hz, NH), 7.32 (dt, J = 7.9, 1.5 Hz, 1H), 7.22–7.14
(m, 1H), 7.03–6.94 (m, 2H), 4.34–4.24 (2H, m, 2H), 3.94 (dd,
J= 12.9, 6.6 Hz, 1H), 3.09 (dd, J = 14.1, 3.9 Hz, 1H), 2.86
(dd, J = 14.1, 7.5 Hz, 1H), 1.85 (d, J= 1.2 Hz, 3H). 13C
NMR (75 MHz, DMSO-d6): d 168.82, 159.25, 131.37, 128.29,
126.98, 123.54, 121.74, 73.64, 49.79, 34.60, 22.54. HRMS m/z
[M+Na]+ calcd for C11H13NNaO2S: 246.2798, found:
246.2796. Anal. Calc. for C11H13NO2S: C, 59.17; H, 5.87; N,
6.27. Found: C, 59.21; H, 5.99; N, 6.15.
4.1.3.2. N-[3,4-Dihydro-2H-1,5-benzoxathiepin-(3R)-yl]-p-
nitrobenzenesulfonamide [(R)-12]. A solution of (R)-10 in
CH2Cl2 (5 mL) at rt was added to a round-bottom flask
(250 mL) that contained a solution of p-nitrobenzenesulfonyl
chloride (344 mg, 1.55 mmol), and 1-[3-(dimethylamino)-pro
pyl]-3-ethylcarbodiimide hydrochloride (EDCl, 642 mg,
3.3 mmol) in CH2Cl2 (15 mL). The resulting mixture was stir-
red at rt for 12 h, then cooled to 5 C, and acidified to pH 1
with addition of an aqueous HCl solution (10%), which was
followed by extraction with CH2Cl2/MeOH (9:1, 3  100 ml).
The combined organic layers were washed with H2O and brine,
dried (Na2SO4), filtered and concentrated in vacuum. The mix-
ture was purified by flash chromatography (hexane/EtOAc:
1/0.5) to obtain (R)-12 (183 mg, 33%) as a white solid; mp
160–162 C; [a]D26: +11.5 (c= 1, in MeOH);. 1H NMR
(300 MHz, CDCl3): d 8.41–8.37 (m, 2H), 8.16–8.12 (m, 2H),
7.41 (dd, J= 8.0, 1.7 Hz, 1H), 7.23–7.17 (m, 1H), 7.04–6.99
(m, 2H), 6.07 (d, J = 9.9 Hz, 1H, NH), 4.19 (ddd, J = 12.6,3.7, 1.6 Hz, 1H), 4.09–4.03 (m, 1H), 3.76 (dd, J= 12.5,
1.9 Hz, 1H), 2.96 (dd, J = 14.4, 2.5 Hz, 1H), 2.78 (ddd,
J= 14.5, 5.0, 1.6 Hz, 1H). 13C NMR (75 MHz, CDCl3): d
160.97, 150.27, 147.43, 132.81, 129.62, 128.28, 128.00, 124.70,
122.51, 74.90, 53.28, 37.62. HRMS m/z [M+H]+ calcd for
C15H15N2O5S2: 367.0422, found: 367.0423. Anal. Calc. for
C15H14N2O5S2: C, 49.17; H, 3.85; N, 7.65. Found: C, 49.32;
H, 3.95; N, 7.48.
4.1.3.3. 6-Chloro-4-N-[3,4-dihydro-2H-1,5-benzoxathiepin-
(3R)-yl]pyrimidine-4,5-diamine [(R)-27]. 4,6-
Dichloropyrimidin-5-amine (133 mg, 0.81 mmol) and Et3N
(0.44 mL, 0.0032 mmol) were added to a solution of (R)-10
(100 mg, 0.55 mmol) in n-BuOH, and the reaction mixture
was heated under reflux and stirred for 24 h under an atmo-
sphere of dry argon. The solvent was evaporated in vacuum,
and the reaction mixture was extracted (EtOAc). The organic
layer was washed with H2O and brine, dried (Na2SO4), filtered
and concentrated in vacuum. The crude was purified by flash
chromatography (CH2Cl2/MeOH: 9.9/0.1) to isolate (R)-27
as a yellowish syrup (340 mg, 52%), [a]D
26: +38.4 (c= 1, in
MeOH). 1H NMR (300 MHz, CDCl3): d 8.06 (s, 1H), 7.47
(dd, J = 7.7, 1.7 Hz, 1H), 7.22 (ddd, J= 9.1, 7.4, 1.7 Hz,
1H), 7.07 (dd, J= 8.1, 1.3 Hz, 1H), 7.03 (dt, J = 7.5,
1.4 Hz, 1H), 6.06 (d, J = 9.1 Hz, 1H, NH), 4.86 (ddd,
J= 8.0, 4.8, 2.8 Hz, 1H), 4.50 (ddd, J= 12.5, 3.5, 1.4 Hz,
1H), 3.99 (dd, J= 12.5, 1.8 Hz, 1H), 3.13 (dd, J= 14.4,
2.8 Hz, 1H), 3.08 (ddd, J = 14.3, 4.9, 1.5 Hz, 1H). 13C NMR
(75 MHz, CDCl3): d 161.35, 153.60, 149.18, 143.06, 132.81,
129.38, 128.73, 124.47, 122.72, 122.54, 74.88, 50.17, 36.51.
HRMS m/z [M+H]+ calcd for C13H14N4OSCl: 309.0577,
found: 309.0569.
Anal. Calc. for C13H13N4OSCl: C, 50.57; H, 4.24; N, 18.14.
Found: C, 50.40; H, 4.35; N, 17.99.
4.1.3.4. 6-Chloro-9-[3,4-dihydro-2H-1,5-benzoxathiepin-(3R)-
yl]-9H-purine [(R)-28]. A solution of (R)-27 (654 mg,
2.05 mmol) in triethyl orthoformate (30 ml) was stirred while
concentrated HCl (37%, 1.3 mL) was added in one portion;
then the reaction mixture was stirred at rt for 24 h under an
atmosphere of dry argon. The solvent was removed and the
residue partitioned between CH2Cl2 (50 mL) and H2O
(50 mL), the phases were separated and the organic layer
was washed with H2O and brine, dried (Na2SO4), filtered
and concentrated in vacuum. The crude was purified by flash
chromatography (CH2Cl2/MeOH: 9/0.1) to afford (R)-47 as
a yellowish solid (392 mg, 60%); mp 152–154 C; [a]D26:
+24.2 (c= 1, in MeOH). 1H NMR (300 MHz, CDCl3): d
8.93 (s, 1H), 8.75 (s, 1H), 7.44 (dd, J = 7.7, 1.6 Hz,
1H),7.29–7.24 (m, 1H), 7.13 (dd, J = 8.1, 1.3 Hz, 1H), 7.07
(td, J = 7.6, 1.4 Hz, 1H), 5.49–5.40 (m, 1H), 4.77–4.64 (m,
2H), 3.4–3.31 (m, 2H). 13C NMR (75 MHz, CDCl3): d
159.86, 152.00, 151.58, 151.42, 145.12, 132.33, 131.41, 129.34,
126.97, 124.73, 122.41, 73.54, 55.15, 35.95. HRMS m/z [M
+H]+ calcd for C14H12N4OSCl: 319.0415, found: 319.0412.
Anal. Calc. for C14H11N4OSCl: C, 52.75; H, 3.48; N, 17.58.
Found: C, 52.91; H, 3.52; N, 17.48.
4.1.3.5. 9-[3,4-Dihydro-2H-1,5-benzoxathiepin-(3R)-yl]-9H-
purin-6-ol [(R)-29] and 9-[3,4-dihydro-2H-1,5-ben-
zoxathiepin-(3R)-yl]-9H-purin-6-amine [(R)-30]. A solution
of (R)-28 (100 mg, 0.3 mmol) in 1,4-dioxane (5 mL) was
Cysteine-based 3-substituted 1,5-benzoxathiepin derivatives 439heated, and NH4OH (10 mL) was added. The reaction mixture
was stirred under reflux for 6 h, then the solvent was removed
in vacuum and the residue was purified by column chromatog-
raphy (CH2Cl2/MeOH: 9.9/0.1) to give (R)-29 and (R)-30.
(R)-29: White solid (13 mg, 14%); mp 140–142 C; [a]D26:
+61.0 (c = 1, in MeOH). 1H NMR (300 MHz, CDCl3): d
12.89 (s, 1H, OH), 8.50 (s, 1H), 8.20 (s, 1H), 7.39 (dd,
J = 7.7, 1.6 Hz, 1H), 7.22 (ddd, J= 8.1, 7.3, 1.7 Hz, 1H),
7.09 (dd, J= 8.1, 1.3 Hz, 1H), 7.04 (dt, J = 7.5, 1.4 Hz,
1H), 5.28–5.26 (m, 1H), 4.74 (d, J = 13.3 Hz, 1H), 4.64 (dd,
J = 13.1, 3.4 Hz, 1H), 3.44 (dd, J= 14.6, 7.5 Hz, 1H), 3.33
(dd, J= 14.5, 4.4 Hz, 1H). 13C NMR (75 MHz, CDCl3): d
159.42, 159.21, 148.75, 145.09, 139.72, 131.96, 128.95, 126.62,
124.38, 122.24, 110.15, 73.45, 55.27, 35.88. HRMS m/z [M
+H]+ calcd for C14H13N4O2S: 301.0754, found: 301.0750.
Anal. Calc. for C14H12N4O2S: C, 55.99; H, 4.03; N, 18.66.
Found: C, 56.11; H, 4.12; N, 18.49.
(R)-30. Yellowish solid (24 mg, 25%); mp 231–233 C; [a]D26:
+67.8 (c = 1, in MeOH). 1H NMR (300 MHz, CDCl3): d 8.61
(s, 1H), 8.35 (s, 1H), 7.42 (dd, J= 7.8, 1.7 Hz, 1H), 7.25–7.22
(m, 1H), 7.11 (dd, J= 8.1, 1.4 Hz, 1H), 7.05 (dt, J = 7.5,
1.4 Hz, 1H), 6.18 (s, 2H, NH2), 5.33 (dd, J = 7.1, 3.3 Hz,
1H), 4.67 (d, J = 3.1 Hz, 2H), 3.44–3.31 (m, 2H). 13C NMR
(75 MHz, CDCl3): d 152.41, 151.15, 146.77, 140.90, 132.18,
129.11, 127.05, 125.95, 124.53, 122.32, 121.97, 73.65, 54.80,
35.98. HRMS m/z [M+H]+ calcd for C14H14N5OS [M
+H]+: 300.0914, found 300.920. Anal. Calc. for C14H13N5OS:
C, 56.17; H, 4.38; N, 23.40. Found: C, 56.01; H, 4.23; N, 23.10.
4.1.3.6. 9-[3,4-Dihydro-2H-1,5-benzoxathiepin-(3R)-yl]-N,N-
dimethyl-9H-purin-6-amine [(R)-31]. A mixture of (R)-28
(100 mg, 0.3 mmol) and KOtBu (56 mg, 0.5 mmol) in DMF
(5 mL) was heated under microwave irradiation at 180 C for
25 min. The reaction mixture was evaporated in vacuum, and
the residue was purified by flash chromatography (hexane/
EtOAc: 1/1) to afford (R)-31 as a colorless syrup (50 mg,
50%), [a]D
26: +91.6 (c = 1, in MeOH). 1H NMR (300 MHz,
CDCl3): d 8.40 (s, 1H, 1H), 8.34 (s, 1H), 7.38 (dd, J = 7.7,
1.6 Hz, 1H), 7.20 (ddd, J = 8.1, 7.3, 1.7 Hz, 1H), 7.07 (dd,
J = 8.1, 1.4 Hz, 1H), 7.02 (dt, J = 7.5, 1.4 Hz, 1H), 5.32 (s,
1H), 4.72–4.59 (m, 2H), 3.55 (s, 6H, N(CH3)2), 3.41 (dd,
J = 14.6, 7.0 Hz, 1H), 3.31 (dd, J = 14.5, 3.9 Hz, 1H). 13C
NMR (75 MHz, CDCl3): d 159.58, 154.84, 152.08, 150.07,
137.75, 131.96, 128.80, 126.94, 124.24, 122.21, 119.79, 73.66,
54.50, 38.84 (CH3)2), 35.78. HRMS m/z [M+H]
+ calcd for
C16H18N5OS: 328.1227, found: 328.1228. Anal. Calc. for C16-
H17N5OS: C, 58.70; H, 5.23; N, 21.39. Found: C, 58.75; H,
5.27; N, 21.23.
4.1.3.7. 6-Chloro-9-[5,5-dioxide-3,4-dihydro-2H-1,5-ben-
zoxathiepin-(3R)-yl]-9H-purine [(R)-32]. Potassium peroxy-
monosulfate (OxoneTM, 470 mg, 3.1 mmol) in H2O (2 mL)
was added to a solution of (R)-28 (100 mg, 0.31 mmol) in
MeOH (6 mL) and the resulting suspension was stirred at rt
for 2 h. After filtration and washing with H2O and CH2Cl2,
the residue was recrystallized from Et2O to yield (R)-32
(44 mg, 40%) as a white solid; mp: 185–187 C; [a]D26: +35.0
(c= 1, in MeOH). 1H NMR (300 MHz, CDCl3): d 8.71 (d,
J = 1.8 Hz, 1H), 8.54 (s, 1H), 8.02 (dd, J = 7.9, 1.7 Hz, 1H),
7.67 (ddd, J= 8.1, 7.4, 1.7 Hz, 1H), 7.41 (dt, J = 7.7,
1.1 Hz, 1H), 7.32 (dd, J = 8.1, 1.1 Hz, 1H), 5.52 (d,
J = 8.1 Hz, 1H), 4.93–4.83 (m, 1H), 4.70 (d, J = 13.0 Hz,1H), 4.25 (dd, J= 14.9, 8.7 Hz, 1H), 3.82 (dd, J = 15.0,
4.1 Hz, 1H). 13C NMR (75 MHz, CDCl3): d 156.36, 152.21,
151.93, 151.46, 144.69, 136.22, 134.16, 131.81, 128.44, 125.79,
123.51, 74.48, 56.27, 52.38. HRMS m/z [M+H]+ calcd for
C14H12N4O3SCl: 351.7845, found: 351.7849. Anal. Calc. for
C14H11N4O3SCl: C, 47.94; H, 3.16; N, 15.97. Found: C,
48.01; H, 3.20; N, 15.85.
4.1.3.8. 2-({2-[6-Chloro-2-(tributylstannyl)-9H-purin-9-yl]
prop-2-en-1-yl}thio)phenol (33). To a stirred solution of
lithium 2,2,6,6-tetramethylpiperidine (LTMP, 2 g, 14 mmol)
in dry THF (30 mL) was added (R)-28 (884 mg, 2.8 mmol) at
78 C under a positive pressure of dry argon. Following stir-
ring at the same temperature for 10 min, Bu3SnCl (3.8 mL,
14 mmol) was added. After 30 min of stirring at 70 C, the
reaction was quenched by adding an aqueous NH4Cl solution,
and the mixture was partitioned between a saturated aqueous
NaHCO3 solution and EtOAc. The organic layer was purified
by flash chromatography (hexane/EtOAc: 3/1) to obtain 33
(260 mg, 16%) as a yellowish syrup, 1H NMR (300 MHz,
CDCl3): d 8.05 (s, 1H, H80), 7.21 (ddd, J= 7.7, 6.0, 1.7 Hz,
2H), 6.93 (dd, J = 8.2, 1.3 Hz, 1H), 6.77 (td, J = 7.5,
1.3 Hz, 1H), 6.56 (s, 1H, OH), 5.29 (d, J = 1.5 Hz, 1H,
H300), 4.88 (d, J = 1.3 Hz, 1H, H300), 4.25–4.23 (m, 2H),
1.64–1.57 (m, 6H), 1.36 (dt, J= 14.8, 7.4 Hz, 6H), 1.26–1.14
(m, 6H), 0.89 (t, J = 7.3 Hz, 9H). 13C NMR (75 MHz,
CDCl3): d 182.78 (C200), 157.37, 150.43, 149.92, 142.89,
138.17, 136.25, 132.00, 130.90, 120.94, 116.67, 115.37, 111.35,
38.73, 29.10 (t, 3J(13C-119Sn) 10.5 Hz, [CH3CH2CH2CH2]3Sn),
27.44 (t, 2J(13C-119Sn) 27.1 Hz [CH3CH2CH2CH2]3Sn), 13.88
(CH3(CH2)3]Sn), 10.91 (t,
1J(13C-119Sn) 165.3 Hz, [CH3(-
CH2)2CH2]3Sn, 12.7 [CH3(CH2)3]3Sn). HRMS m/z [M+H]
+
calcd for C26H38N4OSSnCl: 609.1471, found: 609.1468. Anal.
Calc. for C26H37N4OSSnCl: C, 51.38; H, 6.14; N, 9.22. Found:
C, 51.23; H, 5.99; N, 9.23.
4.1.3.9. 2-{[2-(6-Chloro-2-iodo-9H-purin-9-yl)prop-2-en-1-yl]
thio}phenol (34). A solution of 33 (216 mg, 0.35 mmol) and
iodine (90 mg, 0.35 mmol) in dry THF (5 ml) was stirred at
rt for 24 h under a nitrogen atmosphere. The reaction mixture
was diluted with a 5% aqueous Na2S2O3 and extracted (CH2-
Cl2, 3  100 ml). The extract was washed with brine, dried
(Na2SO4), filtered and concentrated in vacuum. The mixture
was purified by flash chromatography (hexane/EtOAc: 5/1)
to give 34 (71 mg, 68%) as a yellowish solid; mp: 136–
138 C; 1H NMR (300 MHz, CDCl3): d 8.05 (s, 1H, H80),
7.21–7.14 (m, 2H), 6.90 (dd, J = 8.1, 1.3 Hz, 1H), 6.74 (dt,
J= 7.5, 1.3 Hz, 1H), 6.36 (s, 1H, OH), 5.30 (d, J = 1.6 Hz,
1H, H300), 5.04 (d, J = 1.9 Hz, 1H, H300), 4.14 (s, 2H, H100).
13C NMR (75 MHz, CDCl3): d 156.95, 151.63, 150.94,
144.46, 138.00, 135.83, 132.15, 131.99, 121.03, 117.00, 116.35,
115.39, 112.95, 38.15. HRMS m/z [M+H]+ calcd for C14H12-
N4OSClI: 444.9381, found: 444.9391. Anal. Calc. for C14H10-
N4OSClI: C, 37.81; H, 2.27; N, 12.60. Found: C, 37.68; H,
2.28; N, 12.45.
4.2. Density functional theory (DFT) computations
Three-dimensional structures of the compounds were initially
built using the online version of Corina (https://www.mn-
am.com/online_demos/corina_demo), which ascribes to 3D
440 N. Mahfoudh et al.structures pre-defined bond lengths and angles depending on
the type of bond, type of atom and hybridization state. Corina
also defines the most probable torsional angles according to
the nature of the structure (acyclic, small/medium rings,
macro/polycyclic, etc.), being able to correctly reproduce a
varied number of X-ray structures (Gasteiger et al., 1990).
Transition ground state geometries were then calculated in
Spartan 14 using the DFT B3LYP functional combined with
the 6-31G* basis set (Shao et al., 2006). Although Spartan
allows some calculations to be performed in THF, we per-
formed all the simulations in vacuum because our transition
state structures displayed some elements not parameterized
for solvation in THF.
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